These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 17101045

  • 1. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
    Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E, Skribek H, Szekely L.
    BMC Cancer; 2006 Nov 13; 6():265. PubMed ID: 17101045
    [Abstract] [Full Text] [Related]

  • 2. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
    Markasz L, Vanherberghen B, Flaberg E, Otvös R, Stuber G, Gustafsson Jernberg A, Olah E, Skribek H, Szekely L.
    Biomed Pharmacother; 2009 Jul 13; 63(6):413-20. PubMed ID: 18834693
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. EBV transformation overrides gene expression patterns of B cell differentiation stages.
    Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Küppers R.
    Mol Immunol; 2008 Jun 13; 45(11):3133-41. PubMed ID: 18430472
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.
    J Clin Oncol; 2005 Sep 20; 23(27):6481-8. PubMed ID: 16170157
    [Abstract] [Full Text] [Related]

  • 9. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R.
    Autoimmun Rev; 2007 Dec 20; 7(2):96-101. PubMed ID: 18035317
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW.
    J Clin Oncol; 2009 Jul 10; 27(20):3354-62. PubMed ID: 19451438
    [Abstract] [Full Text] [Related]

  • 12. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR, Nalesnik MA, Swerdlow SH.
    Am J Surg Pathol; 2006 Dec 10; 30(12):1604-12. PubMed ID: 17122518
    [Abstract] [Full Text] [Related]

  • 13. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas.
    Swinnen LJ.
    Semin Oncol; 2000 Aug 10; 27(4):402-8. PubMed ID: 10950366
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep 10; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct 10; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 18. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma.
    Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV.
    Blood Cells Mol Dis; 1998 Jun 10; 24(2):114-23. PubMed ID: 9628848
    [Abstract] [Full Text] [Related]

  • 19. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
    Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, Diestelhorst J, Oschlies I, Hussein K, Pape L, Baumann U, Tönshoff B, Pohl M, Höcker B, Wingen AM, Klapper W, Kreipe H, Schulz TF, Klein C, Maecker-Kolhoff B.
    Transplantation; 2013 Jan 15; 95(1):247-55. PubMed ID: 23222899
    [Abstract] [Full Text] [Related]

  • 20. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J, Kotloff R, Tsai DE.
    Transpl Int; 2006 Apr 15; 19(4):259-69. PubMed ID: 16573540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.